Woodline Partners’s Aligos Therapeutics ALGS Stock Holding History

Woodline Partners’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Hold	177,362	–	–	﹤0.01%	914
2026 Q1	$1.32M	Sell	177,362 -111,807	-39%	-$848K	0.01%	848
2025 Q4	$2.7M	Sell	289,169 -179,030	-38%	-$1.69M	0.01%	736
2025 Q3	$4.59M	Sell	468,199 -50,101	-10%	-$458K	0.02%	589
2025 Q2	$3.74M	Buy	518,300 +202,917	+64%	+$1.21M	0.02%	613
2025 Q1	$2.6M	Buy	+315,383	New	+$6.91M	0.02%	626
2024 Q4	–	Sell	-91,971	Closed	-$796K	–	921
2024 Q3	$796K	Buy	91,971 +70,723	+333%	+$880K	0.01%	521
2024 Q2	$186K	Buy	+21,248	New	+$374K	﹤0.01%	534

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners's ALGS Position: Q2 2026 in Review

Woodline Partners held its Aligos Therapeutics (ALGS) position steady in Q2 2026 at 177,362 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #914.

Woodline Partners first reported a position in ALGS in Q2 2024 and has held it in 8 quarters since. The position peaked at $4.59M in Q3 2025. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

Woodline Partners held 177,362 shares of Aligos Therapeutics worth $1.02M as of Q2 2026.
Woodline Partners left its Aligos Therapeutics share count unchanged in Q2 2026.
Aligos Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #914 holding.
Woodline Partners first reported a position in Aligos Therapeutics in Q2 2024 and has held it in 8 quarters since.
Woodline Partners's Aligos Therapeutics position peaked at $4.59M in Q3 2025.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.